Nykode Therapeutics ASA announced that it has been uplisted to the main list of the Oslo Stock Exchange with first day of trading today, June 16, 2022.
OSLO, Norway, June 16, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (Oslo Stock Exchange (OSE): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, today announced that it has been uplisted to the main list of the Oslo Stock Exchange (OSE) with first day of trading today, June 16, 2022. Nykode Therapeutics had traded on the Euronext Growth trading platform in Oslo since October 2020.
“Today, Nykode reached a significant inflection point, signaling our growth as a leading member of the biotech industry in Europe. Nykode’s uplisting to the main list of the Oslo Stock Exchange enables us to reach a broader base of global institutional investors, increase liquidity of the Company’s shares, and better showcase our value proposition as a leading immunotherapy company with a unique and highly differentiated technology platform,” commented Michael Engsig, Chief Executive Officer.
Watch our video to learn more: https://nykode.com/about-us/company-profile.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery
and development of vaccines and novel immunotherapies for the treatment of cancer and infectious diseases. Nykode’s modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses.
Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive interim efficacy and safety results from its Phase II trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group, and is in Phase 1b for the treatment of locally advanced and metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode has initiated a Phase 1/2 trial with two next-generation COVID-19 vaccine candidates.
The Company’s partnerships include Genentech within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development.
Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at www.nykode.com.
Contact for Nykode Therapeutics ASA:
CFO Harald Gurvin
Nykode Therapeutics ASA
IR@nykode.com
Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
